T H 17 lymphocytes appear to be essential in the pathogenesis of numerous inflammatory diseases. We demonstrate here the expression of IL-17 and IL-22 receptors on blood-brain barrier endothelial cells (BBB-ECs) in multiple sclerosis lesions, and show that IL-17 and IL-22 disrupt BBB tight junctions in vitro and in vivo. Furthermore, T H 17 lymphocytes transmigrate efficiently across BBB-ECs, highly express granzyme B, kill human neurons and promote central nervous system inflammation through CD4 + lymphocyte recruitment.
T-helper type 1 (T H 1) 1,2 and type 17 (T H 17) lymphocytes contribute to autoimmune inflammatory diseases 3 including multiple sclerosis and its mouse model, experimental autoimmune encephalomyelitis (EAE) 4, 5 . Disruption of the BBB and trafficking of autoreactive T cells from the systemic compartment into the central nervous system (CNS) are important, early events in the development of multiple sclerosis lesions 6 . In support of T H 1 lymphocytes have been shown to migrate efficiently across the human BBB 7, 8 . To evaluate T H 17 lymphocyte migration to the brain relative to T H 1 cells, we employed an in vitro model of the human BBB using human brain-derived microvascular endothelial cells. We generated human T H 1 and T H 17 lymphocytes in vitro using peripheral blood CD4 + lymphocytes cultured with IL-12 and IL-23, respectively (Supplementary Methods online). Human T H 17 lymphocytes migrated more avidly across the BBB than did T H 1 or freshly isolated (ex vivo) CD4 + lymphocytes ( Fig. 1a , P o 0.01). To ensure that the selective accumulation of T H 17 lymphocytes indeed reflects the preferential transmigration ability of T H 17 cells, we analyzed the intracellular cytokine profile of the cell population before and after migration across BBB-ECs, looking specifically at IL-17 and at IL-22, a recently identified cytokine product of T H 17 cells [9] [10] [11] . We noted a significant enrichment in the number of IL-17-and IL-22-expressing CD4 + CD45RO + memory lymphocytes upon migration across the BBB (Fig. 1b, P o 0 .001 for IL-17 + and P o 0.05 for IL-22 + cells, n ¼ 3), confirming the ability of T H 17 lymphocytes to cross the BBB in vitro. To further substantiate these observations, we generated myelin oligodendrocyte glycoprotein (MOG)-specific T H 1 and T H 17 lymphocytes from 2D2 mice in vitro and transferred these separately into T and B lymphocyte-deficient Rag1 À/À mice. Equal numbers of T H cells were found in the CNS of Rag1 À/À mice 7 d after transfer, regardless of whether donor cells were polarized into T H 1 or T H 17 cells, confirming that T H 1 and T H 17 cells primed and expanded in the periphery access the CNS in vivo (Fig. 1c) . To validate these human in vitro and mouse in vivo observations, brain sections from humans with multiple sclerosis and from unaffected controls were immunostained for CD45RO and IL-17 or IL-22. Numerous CD45RO + cells immunopositive for IL-17 or IL-22 were detected in highly infiltrated multiple sclerosis lesions, but not in normal-appearing white matter or non-inflamed brain specimens (Fig. 1d,e) . Taken together, these results emphasize the potential importance of T H 17 lymphocyte infiltration into the CNS and these lymphocytes' consequent involvement in lesion formation in multiple sclerosis and EAE.
So far, the encephalitogenic activity of T H 17 cells has been attributed to IL-17 (refs. 12,13). To investigate whether the action of T H 17 cells extends beyond the proinflammatory influence of IL-17, we explored the possibility that T H 17 cells might express cytolytic molecules and therefore analyzed T H 17 cells for the expression of perforin, granzyme A and B. Notably, whereas virtually no ex vivo CD4 + CD45RO + cells produced cytolytic enzymes (data not shown), granzyme B was expressed in as many as 22.5% of IL-17-producing CD4 + CD45RO + cells and 17.3% of IL-22 + lymphocytes after 6 d of culture with IL-23 (Fig. 1f) . Even more striking is that 60% of cells coexpressing IL-17 and IL-22 also expressed granzyme B (Fig. 1g) . We therefore tested the capacity of granzyme B + T H 17 cells to kill human fetal neuron-enriched cultures and found that they showed considerable cytolytic activity (32.83 ± 2.54%) as compared to unactivated T lymphocytes (6.15 ± 2.37%) (Fig. 1h, P 
We next analyzed IL-17 receptor (IL-17R) and IL-22 receptor (IL-22R) expression on human BBB-ECs, and investigated whether IL-17 and IL-22 influence BBB integrity. IL-17R and IL-22R were detected on the surface of a subset of human BBB-ECs in primary culture ( Fig. 2a; 23% of IL-17R + and 16% of IL-22R + ). In situ, however, IL-17R and IL-22R were undetectable in CNS material from subjects without multiple sclerosis. However, both receptors were strongly expressed on CNS vessels within heavily infiltrated multiple sclerosis lesions, colocalized with caveolin-1, a marker of brain endothelial cells (Fig. 2b,c) .
We further investigated whether brain endothelial IL-17R and IL-22R were functional, and whether IL-17 and IL-22 could affect BBB permeability. Addition of 10 ng/ml of IL-17 or IL-22 to monolayers of human BBB-ECs induced a marked and sustained increase in the diffusion of fluorescence-labeled BSA (Fig. 2d) . This effect was dose dependent, reached a plateau at 100 ng/ml and coincided, for IL-17, with a decrease in the expression of occludin and zonula occludens (ZO)-1, two important tight junction-associated molecules (Fig. 2e) . A similar reduction of occludin, and to a lesser extent ZO-1, expression was demonstrated by western blotting in spinal cord homogenates from EAE mice (Fig. 2f) . In situ staining further confirmed a decrease in ZO-1 immunoreactivity in cerebellar lesions of MOG-immunized mice (Fig. 2f) These results are in line with our recent data showing a disruption of tight-junction proteins in highly infiltrated vessels of multiple sclerosis lesions 14 . The exact mechanism mediating IL-22-induced BBB permeability remains uncertain, however.
We next explored the capacity of IL-17 and IL-22 to modulate lymphocyte migration across human BBB-ECs and found that IL-17 and IL-22 promote transmigration of human ex vivo CD4 + lymphocytes (Fig. 2g) , most likely through enhanced BBB-EC-mediated secretion of CCL2 (or MCP-1) (Fig. 2h) . IL-17 also induced IL-6 and CXCL8 (or IL-8) expression by BBB-ECs, whereas expression of TGF-b, ICAM-1, VCAM-1, CCL5 (or RANTES) and CXCL10 (or IP-10) remained unaffected (data not shown). Taken together, these results strongly suggest that T H 17 cells, through the action of IL-17 and IL-22, play a unique role in permeabilizing the human BBB both to soluble molecules and to circulating CD4 + lymphocytes.
Our study further refines the phenotype of human T H 17 lymphocytes as cells coexpressing IL-17, IL-22 and granzyme B, and provides strong evidence that IL-17 and IL-22 induce a breach in the BBB and promote the recruitment of additional CD4 + lymphocytes. Although IL-22 has the potential to influence the ability of T H 17 lymphocytes to gain access to the CNS, in vivo evidence indicates that IL-22 does not directly affect their encephalitogenicity (B.B., personal communication). We postulate that T H 17 cells produce multiple mediators contributing to their highly encephalitogenic potential, among them cytolytic enzymes such as granzyme B. 
